AUA 2017: Blue Light Cystoscopy for Detection of Bladder Cancer Recurrence
In the surveillance setting, blue light flexible cystoscopy with the optical imaging agent Cysview detected bladder cancer recurrence in 21.5% of patients that reportedly would have been missed with white light, according to the results of a multicenter phase III study presented by Siamak Daneshmand, MD, Associate Professor of Urology at the University of Southern California Keck School of Medicine, and colleagues, at the 2017 American Urological Association (AUA) Annual Meeting (Abstract PPTLBA-02). White light cystoscopy is the current standard of care for bladder cancer surveillance.
“This study shows that blue light flexible cystoscopy can provide a significant advantage for patients in terms of early detection of tumor recurrence, which may improve treatment and therefore lead to better outcomes,” said J. Stephen Jones, MD, one of the study’s lead investigators and President of Cleveland Clinic Regional Hospitals and Family Health Centers.
The comparative, within-patient controlled study included 304 patients with non–muscle-invasive bladder cancer from 17 academic institutions in the United States. Notably, 9 of 26 patients (34.6%) in the study with flat, more aggressive high-grade lesions were diagnosed using confirmatory blue light cystoscopy with Cysview alone. Repeated administration of Cysview was not associated with an increase in adverse events.